基于MRI的T1rho和T2软骨成分成像在骨关节炎中的应用:我们学到了什么以及临床和试验应用还需要什么
本文综述了基于MRI的T1rho和T2软骨成分测量技术,该技术可表征软骨基质质量并在不可逆缺损出现前诊断软骨损伤。经标本研究和关节镜验证,纵向研究证实其能预测退行性病变进展和放射学骨关节炎(OA)的发生。尽管在早期疾病阶段显示出前景,但临床应用仍面临软骨分割困难、采集时间长、成像缺乏标准化以及缺乏参考数据库和异常阈值定义等障碍。深度学习自动分割和快速成像方法以及RSNA定量成像生物标志物联盟标准化档案的建立已取得进展,多中心可行性测试正在进行中。
要点
- T1rho和T2软骨测量已被组织学和关节镜验证,可表征软骨退变。
- 纵向研究显示其能预测软骨退变进展和放射学OA发生。
- 临床和试验应用需解决标准化、自动分割和参考数据库问题。
英文原文(摘要)· 点击展开
Cartilage MRI-based T1rho and T2 compositional measurements have been developed to characterize cartilage matrix quality and diagnose cartilage damage before irreversible defects are found, allowing intervention at an early, potentially reversible disease stage. Over the last 2 decades, this technology was investigated in numerous studies and was validated using specimen studies and arthroscopy; and longitudinal studies documented its ability to predict progression of degenerative disease and radiographic osteoarthritis (OA). While T1rho and T2 measurements have shown promise in early disease stages, several hurdles have been encountered to apply this technology clinically. These include (i) challenges with cartilage segmentation, (ii) long image acquisition times, (iii) a lack of standardization of imaging, and (iv) an absence of reference databases and definitions of abnormal cut-off values. Progress has been made by developing deep-learning based automatic cartilage segmentation and faster imaging methods, enabling the feasibility of T1rho and T2 imaging for clinical and scientific trial applications. Also, the Radiological Society of North America (RSNA) Quantitative Imaging Biomarker Alliance mechanism was used to establish standardized profiles for compositional T1rho and T2 imaging, and multi-center feasibility testing is work in progress. The last hurdles are the development of reference databases and establishing a definition of normal versus abnormal cartilage T1rho and T2 values. Finally, effective treatments for prevention and slowing progression of OA are required in order to establish T1rho and T2 as imaging biomarkers for initiating and monitoring therapies, analogous to the role of dual X-ray absorptiometry (DXA) bone mineral density measurements in the management of osteoporosis. KEY POINTS: • T1rho and T2 cartilage measurements have been validated in characterizing cartilage degenerative change using histology and arthroscopy as a reference. • They have also been shown to predict progression of cartilage degeneration and incidence of radiographic OA. • Advances have been made to facilitate clinical and trial application of T1rho and T2 by improved standardization of imaging and by establishing deep learning-based automatic cartilage segmentation. • Effective treatments with disease-modifying OA specific drugs may establish T1rho and T2 cartilage compositional measurements as biomarkers to initiate and monitor treatment.
引用
- Link, Joseph, Li, et al. MRI-based T1rho and T2 cartilage compositional imaging in osteoarthritis: what have we learned and what is needed to apply it clinically and in a trial setting? Skeletal Radiol. 2023. PMID: 37000230. doi:10.1007/s00256-023-04310-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。